PURPOSE The purpose of this study was to compare and contrast the clinical characteristics of the triple negative breast cancer (TNBC) and non-TNBC patients, with a particular focus on genetic susceptibility and risk factors prior to diagnosis. METHODS Our institutional database was queried for all patients diagnosed with invasive breast cancer between January 2010 and May 2016. RESULTS Out...

Triple-negative breast cancer (TNBC) is considered one of the most aggressive forms with poor survival rates compared to other subtypes. TNBC characterized by absence estrogen receptor alpha, progesterone receptor, and human epidermal growth factor 2, limiting those viable treatment options available patients Furthermore, due particularly high heterogeneity TNBC, conventional treatments such as...

Metastatic tumour recurrence due to failed treatments remains a major challenge of breast cancer clinical management. Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer (TNBC), where it acts to drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment. We sho...

Breast cancer is one of the most commonly diagnosed cancers and significant sources mortality. Triple negative breast (TNBC) a particularly aggressive subtype that has proven difficult to treat with standard chemotherapies. Obesity also been shown exacerbate cancer, diagnoses these two diseases frequently overlap. Both conditions are regulated in part by fat mass obesity-associated (FTO) demeth...

Triple-negative breast cancer (TNBC), which is estrogen receptor (ER)-negative, progesterone receptor‑negative and is also negative for HER2 expression, remains a great clinical challenge due to its strong resistance to chemotherapy at the late stage of treatment and relatively unfavorable prognosis. Gemcitabine has been approved by the FDA/SFDA for use as a first-line therapeutic drug against ...

Better knowledge of the biology of breast cancer has allowed the use of new targeted therapies, leading to improved outcome. High-throughput technologies allow deepening into the molecular architecture of breast cancer, integrating different levels of information, which is important if it helps in making clinical decisions. microRNA (miRNA) and protein expression profiles were obtained from 71 ...

Background: Triple-negative breast cancer (TNBC) is determined by the absence of ERBB2, estrogen and progesterone receptors’ expression. Cancer vaccines, as the novel immunotherapy strategies, have emerged as promising tools   for treating the advanced stage of TNBC. The aim of this study was to evaluate Carcinoembryonic antigen (CEA), Metadherin (MTDH), and Mucin 1 (MUC-1) proteins as vaccine ...

Triple negative breast cancer (TNBC) is non-responsive to conventional anti-hormonal and Her2-targeted therapies, making it necessary to identify new molecular targets for therapy. Long non-coding RNA anti-differentiation ncRNA (lncRNA DANCR) was identified participating in carcinogenesis of hepatocellular carcinoma, but its expression and potential role in TNBC progression is still unclear. In...

Triple-negative breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified six distinct TNBC subtypes, each displaying a unique biology. Exploring novel approaches to treatment of these subtypes is critical because less than 30%of womenwithmetastatic breast cancer survive five years and virtually all women with metastatic TNBC will ultimately die of their dise...

Abstract Purpose of Review Triple-negative breast cancer (TNBC) is notoriously difficult to treat. Recent technological advances have led the identification novel targets and new approaches treat this devastating disease. The aim review highlight therapeutic vulnerabilities TNBC discuss strategies. Findings Interrogating inherent heterogeneity rich cellular transcriptional diversity within has ...